Topics

Gliomas | Etiopathogenesis | IDH mutations

Home > Publications > Topics > Gliomas > Etiopathogenesis > IDH mutations

Kitagawa Y, Kobayashi A, Cahill DP, Wakimoto H, Tanaka S.
Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.
Biochim Biophys Acta Rev Cancer. 2024 Apr 21;1879(3):189102. doi: 10.1016/j.bbcan.2024.189102. PMID: 38653436. Review˰ ˍ

Choate KA, Pratt EPS, Jennings MJ, Winn RJ, Mann PB.
IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications.
Biology (Basel). 2024 Oct 30;13(11):885. doi: 10.3390/biology13110885. PMID: 39596840. Review. ˍ

Jiang H, Wang X, Chen X, Zhang S, Ren Q, Li M, Li M, Ren X, Lin S, Cui Y.
Unraveling the heterogeneity of WHO grade 4 gliomas: insights from clinical, imaging, and molecular characterization.
Discov Oncol. 2025 Feb 3;16(1):111. doi: 10.1007/s12672-025-01811-0. PMID: 39899184. Observational study. ˍ

Park JW, Kwak J, Kim KW, Jung S, Nam CH, Kim HJ, Lee SM, Choi C, Ahn Y, Park JH, Yoo J, Shim JK, Cho HJ, Kim EH, Kim C, Ahn S, Pusch S, von Deimling A, Chang JH, Kim SH, Kim H, Ju YS, Kang SG, Lee JH.
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation.
Science. 2026 Jan 8;391(6781):eadt0559. doi: 10.1126/science.adt0559. PMID: 41505555. Laboratory investigation˰ ˍ
COMMENT
Mount CW, Suvà ML. The source of IDH-mutant gliomas. Science. 2026 Jan 8;391(6781):125-126. doi: 10.1126/science.aed6843. PMID: 41505560. Comment˰ ˍ